The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
CAR-T cells, bispecific antibodies, and newer immunotherapies are expanding treatment options and improving outcomes for patients with multiple myeloma.
This review tracks the development of CAR-T cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma treatment. It synthesizes current clinical evidence and maps the shifting therapeutic landscape for this hematologic malignancy.
What the study was
- Study design
- Narrative review
- Population
- Multiple myeloma patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
Comprehensive immunotherapy review for myeloma from Lonial/Emory group. Relevant to both hem-malignancy and novel therapeutics watchlists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.